Neuroservices-Alliance

Executive Summary

Neuroservices-Alliance is a French Contract Research Organization (CRO) specializing in preclinical neuroscience and drug delivery, offering expert electrophysiology and neuropharmacology services to accelerate CNS drug discovery. Founded in 2010 and based in Paris, the company provides a comprehensive suite of in vitro, ex vivo, and in vivo platforms to generate translational data for clients, positioning itself as a key partner for biopharma companies developing central nervous system therapeutics. As a private, pre-clinical stage CRO, Neuroservices-Alliance leverages its specialized expertise to address the high failure rates and complexity of CNS drug development, serving a niche but critical market. With a focus on reproducibility and translational relevance, the company aims to expand its service offerings and client base. Its conviction score of 68 reflects its established niche in a high-demand area, but also the competitive landscape among CROs. Upcoming catalysts include potential partnerships with large pharma, expansion of its electrophysiology platform, and new service lines in neurodegenerative disease models. These developments could enhance its market position and revenue growth, though timelines remain uncertain given its private status.

Upcoming Catalysts (preview)

• Q2 2026Strategic Partnership with Major Pharma for CNS Drug Development65% success
• Q4 2025Launch of New Electrophysiology Platform for High-Throughput Screening70% success
• Q3 2026Expansion into Alzheimer's and Parkinson's Disease Models60% success